Antiarrhythmic Agent Currently in Short Supply

Due to ongoing manufacturing issues Norpace CR continues to be in short supply
Due to ongoing manufacturing issues Norpace CR continues to be in short supply

Pfizer has issued an update regarding the availability of Norpace CR (disopyramide phosphate extended-release capsules). 

Due to ongoing manufacturing issues, Norpace CR continues to be in short supply with normal resupply not expected until 2018. Currently, only Norpace CR 100mg in 100-count bottles is available (NDC# 0025-2732-31) through drop shipment; Norpace CR 100mg (500-count bottles), and Norpace CR 150mg (100-count and 500-count bottles) are not available and are on backorder. 

Related Articles

Norpace CR is a Type 1 antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of the drug, its use with lesser arrhythmias is generally not recommended. 

Related Articles

Norpace (disopyramide phosphate capsules) is not affected by this manufacturing event.

For more information visit FDA.gov.